Paul Hastings LLP advised Oppenheimer & Co. as the sole bookrunner in connection with Vaxart, Inc.’s (Nasdaq: VXRT) underwritten offering of 50,000,000 shares of its common stock. The offering is expected to close on or about June 17, 2024, subject to customary closing conditions.

Co-head of Equity Capital Markets and Co-chair of the Corporate Life Sciences Group Seo Salimi led the Paul Hastings team, which also included partner Will Magioncalda and associate Chris Guerin.

More details on the transaction can be found here.

About Paul Hastings

With widely recognized elite teams in finance, mergers & acquisitions, private equity, restructuring and special situations, litigation, employment, and real estate, Paul Hastings is a premier law firm providing intellectual capital and superior execution globally to the world’s leading investment banks, asset managers, and corporations.